Threshold Pharmaceuticals Company Profile (NASDAQ:THLD)

About Threshold Pharmaceuticals (NASDAQ:THLD)

Threshold Pharmaceuticals logoThreshold Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib. Evofosfamide is designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not in healthy tissues. Tarloxotinib is under investigation in two Phase II proof-of-concept trials: one for the treatment of patients with mutant EGFR-positive, T790M-negative advanced NSCLC progressing on an EGFR TKI, and the other for patients with recurrent or metastatic squamous cell carcinomas of the head and neck. [18F]-HX4 is an investigational Positron Emission Tomography imaging agent for hypoxia to identify and quantify the degree of hypoxia in tumors in vivo.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:THLD
  • CUSIP: 88580720
  • Web:
  • Market Cap: $33.72 million
  • Outstanding Shares: 71,591,000
Average Prices:
  • 50 Day Moving Avg: $0.51
  • 200 Day Moving Avg: $0.52
  • 52 Week Range: $0.35 - $1.48
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.27
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.28 per share
  • Price / Book: 1.69
  • EBIDTA: ($23,940,000.00)
  • Return on Equity: 101.72%
  • Return on Assets: 79.46%
  • Current Ratio: 7.96%
  • Quick Ratio: 7.96%
  • Average Volume: 842,147 shs.
  • Beta: 4.85
  • Short Ratio: 0.88

Frequently Asked Questions for Threshold Pharmaceuticals (NASDAQ:THLD)

What is Threshold Pharmaceuticals' stock symbol?

Threshold Pharmaceuticals trades on the NASDAQ under the ticker symbol "THLD."

How were Threshold Pharmaceuticals' earnings last quarter?

Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) posted its quarterly earnings data on Monday, May, 15th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. View Threshold Pharmaceuticals' Earnings History.

Where is Threshold Pharmaceuticals' stock going? Where will Threshold Pharmaceuticals' stock price be in 2017?

1 brokers have issued twelve-month price targets for Threshold Pharmaceuticals' shares. Their forecasts range from $0.52 to $0.52. On average, they anticipate Threshold Pharmaceuticals' stock price to reach $0.52 in the next twelve months. View Analyst Ratings for Threshold Pharmaceuticals.

Are investors shorting Threshold Pharmaceuticals?

Threshold Pharmaceuticals saw a increase in short interest in the month of April. As of April 13th, there was short interest totalling 2,299,725 shares, an increase of 61.4% from the March 31st total of 1,425,262 shares. Based on an average daily volume of 320,444 shares, the days-to-cover ratio is currently 7.2 days. Approximately 3.5% of the shares of the company are sold short.

Who are some of Threshold Pharmaceuticals' key competitors?

Who owns Threshold Pharmaceuticals stock?

Threshold Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include First Eagle Investment Management LLC (9.91%), Vanguard Group Inc. (3.31%), Renaissance Technologies LLC (0.76%), Geode Capital Management LLC (0.57%), FMR LLC (0.56%) and California Public Employees Retirement System (0.28%). View Institutional Ownership Trends for Threshold Pharmaceuticals.

Who sold Threshold Pharmaceuticals stock? Who is selling Threshold Pharmaceuticals stock?

Threshold Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Threshold Pharmaceuticals.

Who bought Threshold Pharmaceuticals stock? Who is buying Threshold Pharmaceuticals stock?

Threshold Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and Geode Capital Management LLC. View Insider Buying and Selling for Threshold Pharmaceuticals.

How do I buy Threshold Pharmaceuticals stock?

Shares of Threshold Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Threshold Pharmaceuticals stock cost?

One share of Threshold Pharmaceuticals stock can currently be purchased for approximately $0.47.

Analyst Ratings

Consensus Ratings for Threshold Pharmaceuticals (NASDAQ:THLD) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $0.52 (10.40% upside)

Analysts' Ratings History for Threshold Pharmaceuticals (NASDAQ:THLD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/3/2016William BlairReiterated RatingOutperformN/AView Rating Details
9/30/2016S&P Equity ResearchLower Price Target$0.67 -> $0.52N/AView Rating Details
12/7/2015Piper Jaffray CompaniesDowngradeOverweight -> NeutralN/AView Rating Details
12/7/2015Cowen and CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
12/7/2015Stifel NicolausDowngradeBuy -> HoldN/AView Rating Details
10/5/2015Cantor FitzgeraldReiterated RatingBuy$14.00N/AView Rating Details
9/15/2015Royal Bank of CanadaReiterated RatingBuyN/AView Rating Details
6/4/2015MLV & Co.Set Price TargetBuy$14.50N/AView Rating Details
(Data available from 5/24/2015 forward)


Earnings History for Threshold Pharmaceuticals (NASDAQ:THLD)
Earnings by Quarter for Threshold Pharmaceuticals (NASDAQ:THLD)
Earnings History by Quarter for Threshold Pharmaceuticals (NASDAQ:THLD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2017Q1 2017($0.08)($0.07)ViewN/AView Earnings Details
3/27/2017Q4 2016($0.07)($0.05)ViewN/AView Earnings Details
11/7/2016Q3($0.09)($0.08)ViewN/AView Earnings Details
8/1/2016Q216($0.10)($0.10)ViewN/AView Earnings Details
5/5/2016Q1($0.02)($0.11)ViewN/AView Earnings Details
3/10/2016Q4($0.11)$0.86$4.51 million$65.87 millionViewN/AView Earnings Details
11/2/2015Q315($0.14)($0.09)$3.69 million$3.70 millionViewN/AView Earnings Details
7/30/2015Q2($0.14)($0.12)$3.70 million$3.68 millionViewN/AView Earnings Details
4/30/2015($0.14)($0.17)$3.44 million$3.68 millionViewN/AView Earnings Details
3/3/2015Q414($0.13)($0.12)$4.34 million$3.68 millionViewN/AView Earnings Details
11/3/2014Q314($0.12)($0.15)$3.82 million$3.70 millionViewN/AView Earnings Details
8/1/2014($0.13)($0.12)$4.00 million$3.68 millionViewN/AView Earnings Details
5/1/2014($0.10)($0.12)$9.81 million$3.68 millionViewN/AView Earnings Details
3/6/2014Q413($0.10)($0.13)$3.58 million$3.20 millionViewN/AView Earnings Details
11/4/2013Q313($0.14)$0.02$3.15 million$3.20 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.09)($0.16)$2.80 million$2.90 millionViewN/AView Earnings Details
11/2/2012Q312($0.06)($0.06)$2.29 million$1.80 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Threshold Pharmaceuticals (NASDAQ:THLD)
2017 EPS Consensus Estimate: ($0.24)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.06)($0.06)($0.06)
Q2 20171($0.06)($0.06)($0.06)
Q3 20171($0.06)($0.06)($0.06)
Q4 20171($0.06)($0.06)($0.06)
(Data provided by Zacks Investment Research)


Dividend History for Threshold Pharmaceuticals (NASDAQ:THLD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Threshold Pharmaceuticals (NASDAQ:THLD)
Insider Ownership Percentage: 12.97%
Institutional Ownership Percentage: 28.71%
Insider Trades by Quarter for Threshold Pharmaceuticals (NASDAQ:THLD)
Institutional Ownership by Quarter for Threshold Pharmaceuticals (NASDAQ:THLD)
Insider Trades by Quarter for Threshold Pharmaceuticals (NASDAQ:THLD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/18/2015Wilfred E JaegerDirectorBuy25,000$3.75$93,750.00View SEC Filing  
10/13/2014Nipun DavarVPBuy3,000$2.99$8,970.00View SEC Filing  
10/1/2014Hill Ventures SutterMajor ShareholderSell226,657$3.77$854,496.89View SEC Filing  
10/1/2014Jeffrey W BirdDirectorSell238,520$3.77$899,220.40View SEC Filing  
6/20/2014David L AndersonMajor ShareholderSell13,988$4.01$56,091.88View SEC Filing  
1/16/2014Wilfred JaegerDirectorSell96,356$4.86$468,290.16View SEC Filing  
1/15/2014Wilfred JaegerDirectorSell424,956$4.87$2,069,535.72View SEC Filing  
1/10/2014Wilfred JaegerDirectorSell723,900$4.88$3,532,632.00View SEC Filing  
7/15/2013Wilfred E JaegerDirectorSell322,000$5.53$1,780,660.00View SEC Filing  
7/11/2013Wilfred E JaegerDirectorSell178,000$5.51$980,780.00View SEC Filing  
7/5/2013Wilfred E JaegerDirectorSell219,667$5.53$1,214,758.51View SEC Filing  
6/19/2013Wilfred E JaegerDirectorSell2,000$5.50$11,000.00View SEC Filing  
6/18/2013Wilfred E JaegerDirectorSell124,733$5.51$687,278.83View SEC Filing  
6/10/2013Wilfred E JaegerDirectorSell153,600$5.48$841,728.00View SEC Filing  
5/31/2013David L AndersonMajor ShareholderSell266,542$5.72$1,524,620.24View SEC Filing  
5/31/2013Jeffrey W BirdDirectorSell273,181$5.72$1,562,595.32View SEC Filing  
5/22/2013Tillman PearceInsiderSell20,000$5.63$112,600.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Threshold Pharmaceuticals (NASDAQ:THLD)
Latest Headlines for Threshold Pharmaceuticals (NASDAQ:THLD)
DateHeadline logoSHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Threshold Pharmaceuticals, Inc. - THLD - May 23 at 7:35 PM logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of Threshold Pharmaceuticals, Inc. to Molecular Templates, Inc. is Fair to Shareholders - THLD - May 23 at 7:35 PM logoThreshold Pharmaceuticals Reports First Quarter Financial Results - May 16 at 11:59 AM logoThreshold Pharmaceuticals posts 1Q loss - May 16 at 11:59 AM logoThreshold Pharmaceuticals, Inc. (THLD) Announces Quarterly Earnings Results - May 16 at 10:54 AM logoThreshold Pharmaceuticals (THLD) Earns Media Sentiment Score of 0.13 - May 2 at 7:04 PM logoThreshold Pharmaceuticals, Inc. (THLD) to Release Quarterly Earnings on Wednesday - May 1 at 6:50 PM logoThreshold Pharmaceuticals (THLD) Receiving Positive News Coverage, AlphaOne Reports - April 29 at 7:23 PM logoThreshold Pharmaceuticals, Inc. (THLD) Sees Significant Increase in Short Interest - April 28 at 8:56 AM logoThreshold Pharmaceuticals (THLD) Receiving Very Favorable Media Coverage, Report Finds - April 18 at 10:24 AM logoThreshold Pharmaceuticals, Inc. (THLD) Short Interest Up 77.5% in March - April 15 at 7:08 AM logoTHRESHOLD PHARMACEUTICALS INC Financials - April 1 at 6:00 AM logoTHRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - March 29 at 6:38 AM logoThreshold Pharmaceuticals, Inc. (THLD) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS - March 28 at 9:14 AM logoThreshold Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results - March 27 at 7:25 PM logoTHRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements - March 27 at 7:25 PM logo[$$] Molecular Templates to Combine With Threshold Pharmaceuticals - March 21 at 7:59 PM logoWall Street's M&A Chatter From March 17-19 - March 21 at 9:56 AM logoThreshold Pharmaceuticals To Become Molecular Templates Inc. After Merger - March 20 at 6:20 PM logoThreshold Pharma, Molecular Templates to Merge (THLD) - March 18 at 1:16 AM logoThreshold Pharma (THLD) to Merge with Molecular Templates - March 18 at 1:16 AM logoThreshold Pharmaceuticals and Molecular Templates Agree to Combine - March 17 at 8:14 PM logo6:58 am Threshold Pharma will merge with Molecular Templates in an all-stock transaction; Longitude Capital will invest $20 mln at the close of the transaction, including the receipt of additional equity financing commitments of $20 mln - March 17 at 8:14 PM logoThreshold Pharma to Merge with Molecular Templates - March 17 at 8:14 PM logoTHRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or - March 17 at 8:14 PM logoMerck KGaA predicts stable adj EBITDA in 2017 - March 9 at 2:12 AM logo8:12 am Threshold Pharma enters into a collaboration with the National Cancer Institute to study TH-3424 - December 20 at 3:35 PM logoThreshold Pharmaceuticals and National Cancer Institute to Collaborate on Drug Candidate TH-3424 - December 19 at 9:55 AM logoTechnical Reports on Biotech Equities -- Aurinia Pharma, Threshold Pharma, Regeneron Pharma, and INSYS ... - PR Newswire (press release) - December 9 at 9:45 AM



Threshold Pharmaceuticals (THLD) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by Staff